# Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products: Phase 1 study in Poliomyelitis Vaccines (60 participants)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products |
| Sponsor type | Non-US government |
| Study | Clinical Study of the Tolerability, Reactogenicity, and Safety of PoliovacSin in Volunteers Aged 18-60 Years |
| NCT ID | NCT07914244 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Poliomyelitis Vaccines |
| Intervention types | biological, other |
| Target enrollment | 60 |
| Site countries | Russia |
| Posted | 2026-11-03 |
| Planned start | 2018-01-29 |
| Event | Newly registered study |
| Event date | 2026-11-03 |

## Why this score
- Posted in the last two weeks.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07914244). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.